Recce's R327 found effective against E.coli during clinical trial
Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
SPD
1.28%
38.5¢
38.5¢
SOUTHERN PALLADIUM LIMITED - Corporate Spotlight
Market Cap $34.55M
!
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $34.55M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 39.5¢ | 38.5¢ | $4.972K | 12.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 7444 | 1 |
View Market Depth
| Last trade - 15.59pm 28/06/2024 (20 minute delay) ? |
|
|||||
|
Last
38.0¢ |
Change
-0.005 ( 1.33 %) |
||||
| Open | High | Low | Volume | ||
| 39.5¢ | 39.5¢ | 38.0¢ | 6548 | ||
| Last updated 15.59pm 28/06/2024 ? | |||||
| SPD (ASX) Chart |
